

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – June 30, 2006

NOTICE OF STATUS CHANGE

Study 3 will permanently close to patient accrual effective Friday, June 30, 2006. Patient accrual has been met.

NOTE: **Study 2** (patients on EIACs) will remain open to Mayo and the University of Alabama Birmingham (UAB).

Please retain this notice with the protocol.